Archives

PRESENTATION TITLE: Late-Breaking Oral Abstract Presentation: NOUS-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome [...]

Marina joined Nouscom in 2016 as the Chief Operating Officer from Versant Ventures where she was an Operating Principal. Prior to Versant, Marina was at Novartis Pharma in Basel in various senior [...]

Alfredo was previously a co-founder and Chief Scientific Officer of Okairos, leading preclinical and clinical development of several vaccines and monoclonal antibodies against infectious diseases [...]

PRESENTATION TITLE: Nous-209 genetic vaccine encoding shared cancer neoantigens has demonstrated safety and robust immunogenicity in patients with Microsatellite Instable Tumors and is under [...]

Antonella was a co-founder of Okairos and served as the company’s Director of Immunology. Her experience includes the positions of Researcher and Group Leader at IRBM, where she focused her [...]

PRESENTATION TITLE: Viral Vectors Based Cancer Vaccines For Potent And Effective Anti-Tumour T Cell Immunity. Please find the full report below: